These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 34080068)
21. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283 [TBL] [Abstract][Full Text] [Related]
22. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience. Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321 [TBL] [Abstract][Full Text] [Related]
24. Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? Mohty M; Richardson PG; McCarthy PL; Attal M Bone Marrow Transplant; 2015 Aug; 50(8):1024-9. PubMed ID: 25893452 [TBL] [Abstract][Full Text] [Related]
25. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment]. Ning X; Wei X; Guo X; Wei Q; Huang F; Fan Z; Xu N; Sun J; Feng R; Liu Q; Wei Y Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(9):1420-1425. PubMed ID: 34658359 [TBL] [Abstract][Full Text] [Related]
26. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322 [TBL] [Abstract][Full Text] [Related]
27. Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma. Gassiot S; Motlló C; Llombart I; Morgades M; González Y; Garcia-Caro M; Ribera JM; Oriol A Eur J Haematol; 2017 Jun; 98(6):569-576. PubMed ID: 28208219 [TBL] [Abstract][Full Text] [Related]
28. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up. Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation. Fenk R; Giagounidis A; Goldschmidt H; Heinsch M; Rummel M; Kroger N; Boquoi A; Lopez D; Gerrlich C; Baier J; Liesenjohann S; Hauck K; Savickaite I; Mai EK; Aul C; Strapatsas J; Dienst A; Kondakci M; Haas R; Kobbe G Clin Cancer Res; 2020 Nov; 26(22):5879-5886. PubMed ID: 32817078 [TBL] [Abstract][Full Text] [Related]
30. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. Marneni N; Chakraborty R Curr Hematol Malig Rep; 2021 Apr; 16(2):148-161. PubMed ID: 33876390 [TBL] [Abstract][Full Text] [Related]
32. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK J Clin Oncol; 2020 Jun; 38(17):1928-1937. PubMed ID: 32298201 [TBL] [Abstract][Full Text] [Related]
33. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M; Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443 [TBL] [Abstract][Full Text] [Related]
34. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. Joks M; Jurczyszyn A; Machaczka M; Skotnicki AB; Komarnicki M Eur J Haematol; 2015 Feb; 94(2):109-14. PubMed ID: 25039659 [TBL] [Abstract][Full Text] [Related]
35. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M; Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394 [TBL] [Abstract][Full Text] [Related]
37. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Mateos MV; Cavo M; Blade J; Dimopoulos MA; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Krevvata M; Chen Y; Wang J; Kudva A; Ukropec J; Wroblewski S; Qi M; Kobos R; San-Miguel J Lancet; 2020 Jan; 395(10218):132-141. PubMed ID: 31836199 [TBL] [Abstract][Full Text] [Related]
38. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533 [TBL] [Abstract][Full Text] [Related]